Open AccessEfficacy of travoprost for the treatment of patients with glaucoma
Author(s) -
Xiuli Zhang,
Qin Li
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016526
Subject(s) - travoprost , medicine , glaucoma , intraocular pressure , cochrane library , medline , meta analysis , latanoprost , ophthalmology , adverse effect , randomized controlled trial , optometry , political science , law
Background: This study will evaluate the efficacy of travoprost for patients with glaucoma systematically. Methods: A comprehensive literature search will be carried from following literature sources from inception to the present: Cochrane Library, MEDLINE, EMBASE, Web of Science, Google scholar, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. We will only consider randomized controlled trials on assessing the efficacy and safety of travoprost for glaucoma for inclusion. We will use Cochrane risk of bias tool for the methodological quality assessment for each qualified study. If it is possible, we will pool the outcome data, and will perform meta-analysis. Results: This study will systematically evaluate the efficacy and safety of travoprost for glaucoma. Primary outcomes include intraocular pressure (IOP), mean IOP, and mean reduction of IOP. Secondary outcomes consist of diastolic ocular perfusion pressure, central corneal thickness, and quality of life, as measured by 36-Item Short Form Health Survey, and treatment-related adverse events included hyperemia, eye pain, and eye pruritus. Conclusion: The findings of the present study will summarize the updated evidence of travoprost for patients with glaucoma. PROSPERO registration number: PROSPERO CRD42019126956.